Skip to main content
Top
Published in: BMC Urology 1/2013

Open Access 01-12-2013 | Research article

Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer

Authors: Mohammed A Mohammed, Manar F Seleim, Mohga S Abdalla, Hayat M Sharada, Abdel Hady A Abdel Wahab

Published in: BMC Urology | Issue 1/2013

Login to get access

Abstract

Background

Matrix Metalloproteinases (MMPs) are key molecules for tumor growth, invasion and metastasis. Over-expression of different MMPs in tumor tissues can disturb the homeostasis and increase the level of various body fluids. Many MMPs including high molecular weights (HMWs) were detected in the urine of prostate and bladder cancer patients. Our aim here is to assess the usefulness of HMW MMPs as non invasive biomarkers in bilharzial bladder cancer in Egyptian patients.

Methods

The activity of different MMPs including HMW species was determined using zymographic analysis technique in the urine samples procured from sixty six bladder cancer patients (bilharzial and non-bilharzial) as well as hundred healthy control subjects. Also, the correlation between these HMW MMPs activities and different clinico-pathological parameters was investigated.

Results

High frequency of urine MMPs (uMMPs) activity was determined in 63.6% of examined tumor cases, however, none of the control cases showed any uMMPs activity. MMP-9 had the highest activity (62%) followed by MMP9/NGAL (60%), MMP-2 (54.5%), MMP-9 dimer (53%), ADAMTS (25.6%), and the lowest one was MMP-9/TIMP-1 (12%) only. There was no correlation between uMMPs and any of clinico-pathological parameters including age, gender, tumor size and type, bilharziasis, grade, lymph node involvement, and invasion to the prostate. A significant correlation was established only between MMP-9/TIMP-1 activities with the tumor size.

Conclusions

This study revealed that the detection of urinary MMPs including HMWs activity might be sensitive biomarkers for prediction of bladder cancer. It is also demonstrate that the detection of these urinary HMW gelatinases could not differentiate between bilharzial and non bilharzial bladder cancer subtypes.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH: The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer. 1981, 48: 2643-2648. 10.1002/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO;2-C.CrossRefPubMed El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH: The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer. 1981, 48: 2643-2648. 10.1002/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO;2-C.CrossRefPubMed
2.
go back to reference El-Mawla NG, El-Bolkainy MN, Khaled HM: Bladder cancer in Africa: update. Semin Oncol. 2001, 28: 174-178. 10.1016/S0093-7754(01)90089-2.CrossRefPubMed El-Mawla NG, El-Bolkainy MN, Khaled HM: Bladder cancer in Africa: update. Semin Oncol. 2001, 28: 174-178. 10.1016/S0093-7754(01)90089-2.CrossRefPubMed
3.
go back to reference El-Bolkainy MN: Topographic pathology of cancer. 1998, Cairo University, National Cancer Institute, 1 El-Bolkainy MN: Topographic pathology of cancer. 1998, Cairo University, National Cancer Institute, 1
4.
go back to reference El-Aaser AA, El-Merzabani MM, Higgy NA, Kader MM: A study on the aetiological factors of bilharzial bladder cancer in Egypt. 3. Urinary beta-glucuronidase. Eur J Cancer. 1979, 15: 573-583.CrossRefPubMed El-Aaser AA, El-Merzabani MM, Higgy NA, Kader MM: A study on the aetiological factors of bilharzial bladder cancer in Egypt. 3. Urinary beta-glucuronidase. Eur J Cancer. 1979, 15: 573-583.CrossRefPubMed
5.
go back to reference Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, El-Kalawy M, Abd-Elsayed AA, Ismail K, Hablas A, Seifeldin IA, Ramadan M, Wilson ML: The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer causes control CCC. 2008, 19: 421-429. 10.1007/s10552-007-9104-7.CrossRefPubMedPubMedCentral Felix AS, Soliman AS, Khaled H, Zaghloul MS, Banerjee M, El-Baradie M, El-Kalawy M, Abd-Elsayed AA, Ismail K, Hablas A, Seifeldin IA, Ramadan M, Wilson ML: The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer causes control CCC. 2008, 19: 421-429. 10.1007/s10552-007-9104-7.CrossRefPubMedPubMedCentral
6.
go back to reference Babjuk M, Dvorácek J: Diagnosis and therapy of superficial tumors of the urinary bladder. Cas Lek Cesk. 2002, 141: 723-728.PubMed Babjuk M, Dvorácek J: Diagnosis and therapy of superficial tumors of the urinary bladder. Cas Lek Cesk. 2002, 141: 723-728.PubMed
7.
go back to reference Aitken KJ, Bägli DJ: The bladder extracellular matrix. Part I: architecture, development and disease. Nat Rev Urol. 2009, 6: 596-611. 10.1038/nrurol.2009.201.CrossRefPubMed Aitken KJ, Bägli DJ: The bladder extracellular matrix. Part I: architecture, development and disease. Nat Rev Urol. 2009, 6: 596-611. 10.1038/nrurol.2009.201.CrossRefPubMed
8.
go back to reference Vasala K, Turpeenniemi-Hujanen T: Serum tissue inhibitor of metalloproteinase-2 (TIMP- 2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem. 2007, 40: 640-644. 10.1016/j.clinbiochem.2007.01.021.CrossRefPubMed Vasala K, Turpeenniemi-Hujanen T: Serum tissue inhibitor of metalloproteinase-2 (TIMP- 2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem. 2007, 40: 640-644. 10.1016/j.clinbiochem.2007.01.021.CrossRefPubMed
9.
go back to reference Wu Z-S, Wu Q, Yang J-H, Wang H-Q, Ding X-D, Yang F, Xu X-C: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008, 122: 2050-2056. 10.1002/ijc.23337.CrossRefPubMed Wu Z-S, Wu Q, Yang J-H, Wang H-Q, Ding X-D, Yang F, Xu X-C: Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008, 122: 2050-2056. 10.1002/ijc.23337.CrossRefPubMed
10.
go back to reference Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998, 58: 1395-1399.PubMed Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998, 58: 1395-1399.PubMed
11.
go back to reference Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001, 276: 37258-37265. 10.1074/jbc.M106089200.CrossRefPubMed Yan L, Borregaard N, Kjeldsen L, Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001, 276: 37258-37265. 10.1074/jbc.M106089200.CrossRefPubMed
12.
go back to reference Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008, 14: 6610-6617. 10.1158/1078-0432.CCR-08-1136.CrossRefPubMedPubMedCentral Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008, 14: 6610-6617. 10.1158/1078-0432.CCR-08-1136.CrossRefPubMedPubMedCentral
13.
go back to reference Leber TM, Balkwill FR: Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998, 78: 724-732. 10.1038/bjc.1998.568.CrossRefPubMedPubMedCentral Leber TM, Balkwill FR: Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998, 78: 724-732. 10.1038/bjc.1998.568.CrossRefPubMedPubMedCentral
14.
go back to reference Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, Blasi F, Hanemaaijer R: Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res. 2000, 6: 2333-2340.PubMed Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, Blasi F, Hanemaaijer R: Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res. 2000, 6: 2333-2340.PubMed
15.
go back to reference Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD: Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 2006, 94: 569-577. 10.1038/sj.bjc.6602931.CrossRefPubMedPubMedCentral Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD: Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 2006, 94: 569-577. 10.1038/sj.bjc.6602931.CrossRefPubMedPubMedCentral
16.
go back to reference Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001, 57: 675-679. 10.1016/S0090-4295(00)01087-6.CrossRefPubMed Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001, 57: 675-679. 10.1016/S0090-4295(00)01087-6.CrossRefPubMed
17.
go back to reference Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993, 268: 10425-10432.PubMed Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993, 268: 10425-10432.PubMed
18.
go back to reference Toth M, Gervasi DC, Fridman R: Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res. 1997, 57: 3159-3167.PubMed Toth M, Gervasi DC, Fridman R: Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res. 1997, 57: 3159-3167.PubMed
19.
go back to reference Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, Massova I, Mobashery S, Fridman R: Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem. 2000, 275: 17269-17275. 10.1074/jbc.M909538199.CrossRef Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, Massova I, Mobashery S, Fridman R: Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem. 2000, 275: 17269-17275. 10.1074/jbc.M909538199.CrossRef
20.
go back to reference Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008, 14: 2378-2386. 10.1158/1078-0432.CCR-07-1253.CrossRefPubMed Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008, 14: 2378-2386. 10.1158/1078-0432.CCR-07-1253.CrossRefPubMed
21.
go back to reference Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009, 9: 390-10.1186/1471-2407-9-390.CrossRefPubMedPubMedCentral Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009, 9: 390-10.1186/1471-2407-9-390.CrossRefPubMedPubMedCentral
22.
go back to reference Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D: Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2005, 17: 843-848. 10.1097/00042737-200508000-00011.CrossRefPubMed Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D: Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2005, 17: 843-848. 10.1097/00042737-200508000-00011.CrossRefPubMed
Metadata
Title
Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer
Authors
Mohammed A Mohammed
Manar F Seleim
Mohga S Abdalla
Hayat M Sharada
Abdel Hady A Abdel Wahab
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2013
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-13-25

Other articles of this Issue 1/2013

BMC Urology 1/2013 Go to the issue